Arcutis Biotherapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Arcutis Biotherapeutics, Inc. filed a Form 8-K dated September 2, 2022, under Items 5.02, 7.01, and 9.01. The filing reports a board appointment and related Regulation FD disclosure; it does not present quarterly or annual financial results.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
Material Changes
- The Board increased its size from nine to ten directors.
- Neha Krishnamohan was appointed as a Class III director and member of the Audit Committee, effective September 2, 2022.
- Her term is expected to expire at the 2023 annual meeting of stockholders, subject to earlier termination or successor appointment.
- Ms. Krishnamohan has served as Chief Financial Officer and Executive Vice President, Corporate Development of Kinnate Biopharma Inc. since June 2021 and previously held healthcare investment-banking roles at Goldman Sachs.
Compensation, Outlook, and Risks
- Under the non-employee director compensation program, Ms. Krishnamohan received an option to purchase 29,482 shares of common stock. The option vests in three equal annual installments, subject to continued service.
- She is eligible for annual cash retainers of $40,000 for Board service and $10,000 for Audit Committee service.
- The Company will enter into its standard form of indemnification agreement with Ms. Krishnamohan.
- The filing reports no arrangement or understanding relating to her appointment, no applicable family relationships, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
- No management guidance, business outlook, contingencies, or unusual financial items are disclosed.
Important Facts to Verify
- Completion and terms of the indemnification agreement.
- Vesting and accounting treatment of the 29,482-share stock option.
- Ms. Krishnamohan’s continued service on the Board and Audit Committee through the 2023 annual meeting.
- The related appointment press release filed as Exhibit 99.1.